<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>The Meetingpoint at Slavyanski.net / friday5plate / All</title>
<link>https://slavyanski.net/sb2020</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Fri, 28 Aug 2020 15:59:48 +0000</pubDate>
<language>en</language>
<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 28 Aug 2020 15:59:48 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 28 Aug 2020 15:59:14 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-4</guid>
</item>

<item>
	<title><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-6"><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></source>
	<description><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results from testing a unique lot. The dotted lines represent the quality range established based on the adalimumab (US) lots tested (mean ?3 standard deviations). Adalimumab (EU) EU-authorized adalimumab, adalimumab (US) FDA-licensed adalimumab, CDC complementdependent cytotoxicityFunctional Characterization of ABP 501, Bios ]]></description>
	<pubDate>Thu, 27 Aug 2020 15:05:01 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-6</guid>
</item>

<item>
	<title><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-9"><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></source>
	<description><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results from testing a unique lot. The dotted lines represent the quality range established based on the adalimumab (US) lots tested (mean ?3 standard deviations). Adalimumab (EU) EU-authorized adalimumab, adalimumab (US) FDA-licensed adalimumab, CDC complementdependent cytotoxicityFunctional Characterization of ABP 501, Bios ]]></description>
	<pubDate>Thu, 27 Aug 2020 15:04:17 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-9</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-1"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Wed, 26 Aug 2020 17:31:16 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-1</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Mon, 24 Aug 2020 17:00:51 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-1</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Mon, 24 Aug 2020 17:00:21 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-6</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-5"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Sat, 22 Aug 2020 05:38:04 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-5</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-8</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-8"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Sat, 22 Aug 2020 05:37:29 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-8</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Sat, 22 Aug 2020 02:21:28 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Wed, 19 Aug 2020 18:05:11 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-1</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Wed, 19 Aug 2020 17:19:34 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-8</guid>
</item>

<item>
	<title><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9"><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity]]></source>
	<description><![CDATA[To mediate ADCC in vitro [9, 17, 23]. Although the contribution of ADCC activity to clinical efficacy is unclear, it is important to characterize all activities of the candidate mAb, especially those that can be affected by differences in post-translational modifications, such as glycosylation. The ability of ABP 501 to induce ADCC was assessed using MT-3 cells as target cells, and NK-92M1 cells s ]]></description>
	<pubDate>Wed, 19 Aug 2020 17:19:00 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=to-mediate-adcc-in-vitro-9-17-23-although-the-contribution-of-adcc-activity-9</guid>
</item>

<item>
	<title><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-3"><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></source>
	<description><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results from testing a unique lot. The dotted lines represent the quality range established based on the adalimumab (US) lots tested (mean ?3 standard deviations). Adalimumab (EU) EU-authorized adalimumab, adalimumab (US) FDA-licensed adalimumab, CDC complementdependent cytotoxicityFunctional Characterization of ABP 501, Bios ]]></description>
	<pubDate>Tue, 18 Aug 2020 23:08:25 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-3</guid>
</item>

<item>
	<title><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-7"><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results]]></source>
	<description><![CDATA[Alimumab (US) (black), and adalimumab (EU) (blue). Each point represents results from testing a unique lot. The dotted lines represent the quality range established based on the adalimumab (US) lots tested (mean ?3 standard deviations). Adalimumab (EU) EU-authorized adalimumab, adalimumab (US) FDA-licensed adalimumab, CDC complementdependent cytotoxicityFunctional Characterization of ABP 501, Bios ]]></description>
	<pubDate>Tue, 18 Aug 2020 23:07:53 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=alimumab-us-black-and-adalimumab-eu-blue-each-point-represents-results-7</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Mon, 17 Aug 2020 08:33:43 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-7</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Mon, 17 Aug 2020 08:33:14 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Mon, 17 Aug 2020 08:14:20 +0000</pubDate>
	<author>friday5plate</author>
	<category></category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-2</guid>
</item>

<item>
	<title><![CDATA[N of the mAb were shown to be able to discriminate]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-5</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-5"><![CDATA[N of the mAb were shown to be able to discriminate]]></source>
	<description><![CDATA[N of the mAb were shown to be able to discriminate a thermally degraded sample (data not shown), demonstrating that the utilized assays are sensitive to detect differences in activity, if they did exist. It is well established that IgG1 mAbs are efficient mediators of effector function, and are able to bind to many of the known FccRs. A sensitive comparison of these Fcdependent activities is impor ]]></description>
	<pubDate>Fri, 14 Aug 2020 07:52:51 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-5</guid>
</item>

<item>
	<title><![CDATA[N of the mAb were shown to be able to discriminate]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-4</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-4"><![CDATA[N of the mAb were shown to be able to discriminate]]></source>
	<description><![CDATA[N of the mAb were shown to be able to discriminate a thermally degraded sample (data not shown), demonstrating that the utilized assays are sensitive to detect differences in activity, if they did exist. It is well established that IgG1 mAbs are efficient mediators of effector function, and are able to bind to many of the known FccRs. A sensitive comparison of these Fcdependent activities is impor ]]></description>
	<pubDate>Fri, 14 Aug 2020 07:52:28 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=n-of-the-mab-were-shown-to-be-able-to-discriminate-4</guid>
</item>

<item>
	<title><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-8</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-8"><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality]]></source>
	<description><![CDATA[Onstrated since all of the ABP 501 lots fell within the quality range established based on the adalimumab (US) lots tested. Another mechanism for inducing cell death is the induction of CDC in cells expressing mbTNFa. A comparison of the CDC activity of ABP 501 to that of adalimumab (US) and adalimumab (EU) using MT-3 cells as target cells was conducted. Mean (three independent experiments) percen ]]></description>
	<pubDate>Tue, 11 Aug 2020 14:50:13 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=onstrated-since-all-of-the-abp-501-lots-fell-within-the-quality-8</guid>
</item>

<item>
	<title><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3"><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple]]></source>
	<description><![CDATA[Assessment of the bioactivity of adalimumab should include assessment of multiple in vitro endpoints (NFjB-dependent and NFjB-independent) and should include binding to both soluble and transmembrane TNFa. ABP 501 has been shown to be similar to adalimumab in its ability to neutralize TNFa-induced caspase activation, chemokine production, and cytotoxicity, functions inclusive of both NFjB-dependen ]]></description>
	<pubDate>Tue, 11 Aug 2020 13:28:16 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=assessment-of-the-bioactivity-of-adalimumab-should-include-assessment-of-multiple-3</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 07 Aug 2020 04:00:43 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-9</guid>
</item>

<item>
	<title><![CDATA[T assays were conducted, and the mean percent relative activity is]]></title>
	<link>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</link>
	<source url="https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6"><![CDATA[T assays were conducted, and the mean percent relative activity is]]></source>
	<description><![CDATA[T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab  ]]></description>
	<pubDate>Fri, 07 Aug 2020 04:00:15 +0000</pubDate>
	<author>friday5plate</author>
	<category>News</category>
	<votes>1</votes>
	<guid>https://slavyanski.net/sb2020/story.php?title=t-assays-were-conducted-and-the-mean-percent-relative-activity-is-6</guid>
</item>

</channel>
</rss>
